Nanoparticle CLD Case Study

Your complex biologic program requires an experienced partner who can guide you from cell line selection through process development and manufacturing.

Abzena’s extensive expertise and fully integrated cell line development, process optimization, and scale-up capabilities played a key role in a collaboration with a non-profit research institute working on novel biomedical interventions. In this case study, we share how our AbZelectPRO platform approach enabled the successful development of a stable cell line expressing a fusion protein that self-assembles into nanoparticles (NP), resulting in high titers, a robust DSP process, and consistent product quality.

Access the case study to find out how Abzena’s end-to-end CLD solution can accelerate and de-risk your complex biologics program.